Walter Dyne announced that its subsidiary Dyne Pharmaceutical recently received the “Drug Registration Certificate” issued by the State Drug Administration. The name of the drug is clonidine hydrochloride extended-release tablets, which are mainly used alone or as an adjuvant for the treatment of attention deficit hyperactivity disorder in children and adolescents aged 6-17. The approval number for this drug is Sinopharm Standard H20256411, which is valid until December 29, 2030. Obtaining a drug registration certificate this time will help enrich the company's product pipeline in the field of pediatric ADHD treatment and enhance the company's competitiveness.

Walter Dyne announced that its subsidiary Dyne Pharmaceutical recently received the “Drug Registration Certificate” issued by the State Drug Administration. The name of the drug is clonidine hydrochloride extended-release tablets, which are mainly used alone or as an adjuvant for the treatment of attention deficit hyperactivity disorder in children and adolescents aged 6-17. The approval number for this drug is Sinopharm Standard H20256411, which is valid until December 29, 2030. Obtaining a drug registration certificate this time will help enrich the company's product pipeline in the field of pediatric ADHD treatment and enhance the company's competitiveness.